Cemiplimab‐rwlc is the third anti‐PD‐1 antibody approved by the U.S. FDA for the treatment of advanced NSCLC patients with PD‐L1 expression of at least 50%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.